DESIGN THERAPEUTICS INC. - COMMON STOCK

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

07 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

03 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

17 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

22 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

08 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

03 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

01 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

09 May 2022 16:05:01 By Nasdaq GlobeNewswire

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

30 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

10 Mar 2022 16:02:00 By Nasdaq GlobeNewswire

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

09 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia  

28 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

10 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

01 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

09 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

08 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

09 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

07 Jun 2021 16:10:00 By Nasdaq GlobeNewswire

Design Therapeutics Expands Board of Directors with Key Appointments

07 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

10 May 2021 16:05:00 By Nasdaq GlobeNewswire